ポスター1-3 CML：基礎と臨床研究

[PS1-3-1] BCR-ABL mutations and molecular response in patients taking tyrosine kinase inhibitors

Hsueng-Mei Liu¹, Sheng-Hsuan Chien^1,2,3, Po-Ming Chen⁴, Jeong-Shi Lin¹, Ying-Ju Chen¹, Li-Hsuan Lee¹, Po-Shen Ko³, Tzeon-Jye Chiou^1,2, Jyh-Pyng Gau³, Chun-Yu Liu^1,5 (1.Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Outside of the US, Taiwan, 2.Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, Taipei, outside of US, Taiwan, 3.Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, outside of US, Taiwan, 4.Department of Food and Science and biotechnology, National Chung Hsing University, Taichung, outside of US, Taiwan, 5.Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, outside of US, Taiwan)